TITLE

Review: Adjuvant corticosteroid therapy reduces death, hearing loss, and neurologic sequelae in bacterial meningitis: COMMENTARY

AUTHOR(S)
Morris, Andrew M.
PUB. DATE
March 2004
SOURCE
ACP Journal Club;Mar/Apr2004, Vol. 140 Issue 2, p34
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article comments on the study conducted to analyze the efficacy of adjuvant corticosteroid therapy in reducing death, hearing loss, and neurologic sequelae in patients with acute bacterial meningitis (ABM). ABM remains one of the most catastrophic of infectious diseases. Victory against ABM requires the same strategies used against other life-threatening infectious diseases. Although recent vaccine developments against ABM have shifted the proportion of infections to adults in developed countries, ABM continues to threaten both children and adults in developing countries. A recent randomized controlled trial in a study showed that corticosteroids were beneficial in ABM.
ACCESSION #
12597117

 

Related Articles

  • Review: adjuvant corticosteroid therapy reduces death, hearing loss, and neurological sequelae in bacterial meningitis. Morris, Andrew M. // Evidence Based Medicine;Mar/Apr2004, Vol. 9 Issue 2, p48 

    The article informs that adjuvant corticosteroid therapy reduces death, hearing loss, and neurological sequelae in bacterial meningitis. Overall, fewer patients who received corticosteroids died than did those who received placebo; groups did not differ for mortality in 14 studies with children...

  • Novel Adjuvant Systems. McCluskie, Michael J.; Weeratna, Risini D. // Current Drug Targets - Infectious Disorders;Nov2001, Vol. 1 Issue 3, p263 

    Vaccination remains the single most valuable tool in the prevention of infectious disease. Nevertheless, there exists a need to improve the performance of existing vaccines such that fewer boosts are needed or to develop novel vaccines. For the development of effective vaccines for humans, a...

  • Effect of Perioperative Immunosuppressive Medication on Early Outcome in Crohn’s Disease Patients. Indar, Adrian A.; Young-Fadok, Tonia M.; Heppell, Jacques; Efron, Jonathan E. // World Journal of Surgery;May2009, Vol. 33 Issue 5, p1049 

    The aim of the present study was to examine the early outcome in patients undergoing intestinal resection for Crohn’s disease (CD) while they are receiving perioperative immunosuppressive medication. We reviewed patients with CD undergoing intestinal surgery from 1999 to 2007....

  • Efficacy of Adalimumab in Moderate-to-Severe Pediatric Crohn's Disease. Viola, Franca; Civitelli, Fortunata; Di Nardo, Giovanni; Barbato, Maria Beatrice; Borrelli, Osvaldo; Oliva, Salvatore; Conte, Francesca; Cucchiara, Salvatore // American Journal of Gastroenterology;Oct2009, Vol. 104 Issue 10, p2566 

    OBJECTIVES:The use of tumor necrosis factor-alpha (TNF-α) antagonists has changed the therapeutic strategy for Crohn's disease (CD). Adalimumab (ADA), a fully human anti-TNF-α monoclonal antibody, is an effective therapy for patients with CD, both naive patients and those intolerant or...

  • Barrier-Restoring Therapies in Atopic Dermatitis: Current Approaches and Future Perspectives. Valdman-Grinshpoun, Y.; Ben-Amitai, D.; Zvulunov, A. // Dermatology Research & Practice;2012, Vol. 2012, p1 

    Atopic dermatitis is a multifactorial, chronic relapsing, inflammatory disease, characterized by xerosis, eczematous lesions, and pruritus. The latter usually leads to an "itch-scratch" cycle that may compromise the epidermal barrier. Skin barrier abnormalities in atopic dermatitis may result...

  • Adrenocortical carcinoma: effect of hospital volume on patient outcome. Lombardi, Celestino; Raffaelli, Marco; Boniardi, Marco; Toma, Giorgio; Marzano, Luigi; Miccoli, Paolo; Minni, Francesco; Morino, Mario; Pelizzo, Maria; Pietrabissa, Andrea; Renda, Andrea; Valeri, Andrea; Crea, Carmela; Bellantone, Rocco // Langenbeck's Archives of Surgery;Feb2012, Vol. 397 Issue 2, p201 

    Purpose: Optimal management of adrenocortical carcinoma (ACC) involves a detailed diagnostic workup, radical surgery, and appropriate adjuvant therapy. However, due to the rarity of this disease, adequate expertise is necessary to ensure optimal patient care. We evaluated if the experience of a...

  • Immunomodulatory therapy requires careful monitoring. Caceres, Vanessa // Ophthalmology Times;Apr2015, Vol. 40 Issue 6, p40 

    The article discusses the reasons why immunomodulatory treatment for ocular inflammatory disease requires careful monitoring, according to associate ophthalmology professor Ramana S. Moorthy, M.D. Topics mentioned include the appropriate duration of therapy, methotrexate as an antimetabolite...

  • Inhaled corticosteroids and risk of cataract formation. Kirchner, Jeffrey T. // American Family Physician;12/1/1997, Vol. 56 Issue 9, p2333 

    Presents the summary of the article `Use of Inhaled Corticosteroids and the Risk of Cataracts,' by R.G. Cumming from the `Northern England Journal of Medicine' dated 1997. Effects of inhaled corticosteroids; Cumulative lifetime dosage of beclomethasone.

  • Defining the Optimal Response Criteria for the Crohn's Disease Activity Index for Induction Studies in Patients With Mildly to Moderately Active Crohn's Disease. Thia, Kelvin T.; Sandborn, William J.; Lewis, James D.; Loftus, Jr, Edward V.; Feagan, Brian G.; Steinhart, A. Hillary; Hanauer, Stephen B.; Persson, Tore; Sands, Bruce E. // American Journal of Gastroenterology;Dec2008, Vol. 103 Issue 12, p3123 

    OBJECTIVES: The Crohn's Disease Activity Index (CDAI) is used to judge efficacy in clinical trials. We explored the effect of CDAI response definitions for induction on study efficiency. METHODS: We analyzed primary CDAI data from induction studies in patients with mildly to moderately active...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics